The FDA has approved ViiV Healthcare’s Rukobia (fostemsavir) for adults with HIV who could not be successfully treated with other therapies.

The approval was based on the results of a clinical trial in which 53 percent of patients treated with Rukobia achieved low levels of HIV after 24 weeks.

Rukobia was granted fast track, priority review and breakthrough therapy designations by the FDA.